Clinical Trials Logo

Clinical Trial Summary

The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04665674
Study type Observational [Patient Registry]
Source Assistance Publique - Hôpitaux de Paris
Contact Abdellatif TAZI, MD PhD
Phone 142499198
Email abdellatif.tazi@aphp.fr
Status Recruiting
Phase
Start date January 1, 2004
Completion date December 31, 2035

See also
  Status Clinical Trial Phase
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Recruiting NCT05915208 - Histiocytic Disorder Follow-up Study
Recruiting NCT04437381 - Molecular Targets for the Treatment of Histiocytosis
Terminated NCT01050439 - Unrelated Donor Transplant for Malignant and Non-Malignant Disorders Phase 2
Active, not recruiting NCT00145626 - HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase 2
Not yet recruiting NCT05803629 - Characterizing Histiocytosis With 68Ga-FAPI PET/CT N/A
Terminated NCT02012231 - Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Phase 1
Completed NCT01225718 - Ceftriaxone in Non-neutropenic Fever N/A
Active, not recruiting NCT03127709 - A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
Recruiting NCT05786924 - A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Phase 1
Recruiting NCT04943198 - Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis Phase 2
Recruiting NCT04943211 - Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging Phase 3
Recruiting NCT04943224 - Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients Phase 2